scholarly journals Suppression of an Antibody to Factor VIII by a Combination of Factor VIII and Cyclophosphamide

Blood ◽  
1971 ◽  
Vol 37 (4) ◽  
pp. 381-387 ◽  
Author(s):  
DAVID GREEN
Keyword(s):  
Factor Viii ◽  
Vaginal Bleeding ◽  
Blood Clotting ◽  
Intravenous Dose ◽  
Clotting Time ◽  
Factor Viii Activity ◽  
Plasma Factor ◽  
History Of ◽  
Blood Clotting Time

Abstract A 54-year-old woman with a 20-year history of generalized, severe psoriasis presented with diffuse ecchymoses, melena, and vaginal bleeding. The whole blood clotting time was 59 minutes and the plasma factor VIII concentration was less than 1 per cent of normal. Incubation of the patient’s plasma with cryoprecipitate containing one unit of factor VIII resulted in the rapid disappearance of factor VIII activity from the mixture. The major antifactor VIII activity of the patient’s plasma was associated with an immunoglobulin of the IgG class. The patient was initially treated with a combination of methotrexate, azathioprine, and cyclophosphamide. No improvement occurred, and after 6 weeks of therapy the drugs were discontinued. Eight months later, she presented with an expanding sublingual hematoma. Bleeding was controlled by the rapid administration of 10,000 units of factor VIII, and an intravenous dose of cyclophosphamide given concurrently resulted in a prompt decline in antibody titer. Factor VIII levels subsequently became normal and have remained normal during 7 months of follow-up observation.

A Patient with an Unusual Circulating Anticoagulant

1964 ◽  
Vol 12 (01) ◽  
pp. 001-011 ◽  
Author(s):  
Rosemary Biggs ◽  
K. W. E Denson ◽  
H. L Nossel
Keyword(s):  
Factor Viii ◽  
Whole Blood ◽  
Blood Clotting ◽  
Assay Method ◽  
Clotting Time ◽  
High Dilution ◽  
Two Stage ◽  
One Stage ◽  
Blood Clotting Time

SummaryThe investigation of a patient with an inhibitor which destroyed factor VIII is described. The inhibitor was active at high dilution but inactivated only 70–80 per cent of added factor VIII if tested by a two-stage assay method. Using a one-stage method 90–95 per cent of the activity disappeared. Thus, according to the method used, 5–30 per cent of factor VIII remained in the patient’s plasma. No other type of inhibitor was detected, yet the whole blood clotting time was prolonged and experience with haemophilic patients suggests that factor VIII levels between 5 and 30 per cent of normal should be accompanied by normal clotting time.

Non-Decalcified Barium Sulfate-Adsorbed Plasma A Potentially Useful Reagent for Studying Blood Clotting, Platelets or Complement

1982 ◽  
Vol 47 (02) ◽  
pp. 182-184 ◽  
Author(s):  
Marjorie B Zucker ◽  
John Owen
Keyword(s):  
Factor Viii ◽  
Vitamin K ◽  
Divalent Cation ◽  
Barium Sulfate ◽  
Blood Clotting ◽  
Factor V ◽  
Fibrinopeptide A ◽  
Factor Viii Activity ◽  
Clotting Factors ◽  
Plasma Factor

SummaryPlasma was prepared by rapid centrifugation of native blood followed by adsorption of vitamin K-dependent clotting factors with BaSO4. Compared to fresh citrated plasma, BaSO4-treated plasma contained about 80% of factor V and factor VIII and the same concentration of fibrinopeptide A. Assays were also carried out after overnight incubation of citrated plasma and BaSO4-adsorbed plasma with and without added citrate and compared to assays of fresh citrated plasma. Factor V decreased to about 25% in both citrated samples, factor VIII decreased to 45% in both samples of BaSO4-treated plasma, and fibrinopeptide A did not change. Thus loss of factor V activity depended on reduction in divalent cation concentration whereas loss of factor VIII activity may have resulted from effects of early traces of thrombin.

Diagnosis of dengue fever in a patient with early pregnancy loss

2021 ◽  
Vol 14 (8) ◽  
pp. e243968
Author(s):  
Naomi N Adjei ◽  
Anna Y Lynn ◽  
Ernest Topran ◽  
Oluwatosin O Adeyemo
Keyword(s):  
Neonatal Death ◽  
Vaginal Bleeding ◽  
Pregnancy Loss ◽  
Clinical Evidence ◽  
Adverse Outcomes ◽  
Intravenous Fluids ◽  
Early Pregnancy Loss ◽  
Orbital Pain ◽  
History Of

Dengue is a mosquito-borne virus that causes an influenza-like illness ranging in severity from asymptomatic to fatal. Dengue in pregnancy has been associated with adverse outcomes including miscarriage, preterm birth and fetal and neonatal death. We present the case of a multiparous woman who presented at 9 weeks’ gestation with vaginal bleeding and abdominal cramping after a 1 month stay in Mexico. She was initially diagnosed with miscarriage with plan for outpatient follow-up. She was readmitted 3 days later with fever, retro-orbital pain, arthralgia, rash, pancytopenia and transaminitis and managed with intravenous fluids and acetaminophen. Of note, dengue serology was initially negative but retesting 2 days later was positive. It is imperative that clinicians have heightened suspicion for dengue in pregnant women with history of travel to or residence in a dengue-endemic area and consistent clinical evidence.

The Blood-Clotting Time in Spent Silver Salmon, Oncorhynchus kisutch (Walbaum)

Copeia ◽  
1950 ◽  
Vol 1950 (2) ◽  
pp. 150 ◽  
Author(s):  
Max Katz ◽  
Morris Southward
Keyword(s):  
Blood Clotting ◽  
Oncorhynchus Kisutch ◽  
Clotting Time ◽  
Blood Clotting Time

scholarly journals Further Experience on the Effect of High Pre-Donation Factor VIII Levels in Blood Donors on the Factor VIII Content of Small-Pool Fractions

1977 ◽  
Author(s):  
H. Beeser ◽  
H. Eqli
Keyword(s):  
Factor Viii ◽  
High Plasma ◽  
Activity Levels ◽  
Factor Viii Activity ◽  
Factor Viii Level ◽  
Plasma Factor ◽  
Viii Level ◽  
Factor Viii Concentrates ◽  
Small Pool ◽  
Concentrate Preparation

Because of the well known wide normal range of the factor VIII activity between 60 to 170% I man, selecting of donors with high activity levels would be of advantaae for the preparation of factor VIII concentrates. This is especially true for preparing small-pool fractions, as for technical reasons the final product cannot be controlled for its factor VIII content. In preliminary investigations, we reported on elsewhere, high factor VIII activity in donors estimated before a donation had been rarely reproducible before a second donation after 8-12 weeks. So as a preliminary result of finding a donor’s factor VIII level varying from donation to donation selecting of plasmas with high factor VIII content for concentrate preparation could only be establishedby re-estimating the activity before each donation. Proceeding in this way would be much too troublesome. To get more reliable information whether a healthy subject’s high factor VIII plasma level is distinctly varying or rather constant we assayed the plasma of 200 donors with factor VIII activity > 120% two times more before donation. The results confirmed our preliminary findings, especially the fact that a high plasma factor VIII activity in experienced donors was rarely reproducible when re-estimated before a second and third donation. As a consequence selecting of donors with high factor VIII procoaqulant activity for preparing small-pool factor VIII concentrates is impracticable.

Autoprothrombin II of human origin

1961 ◽  
Vol 201 (4) ◽  
pp. 660-662 ◽  
Author(s):  
Orhan N. Ulutin ◽  
J. Frederic Johnson ◽  
Walter H. Seegers
Keyword(s):  
Whole Blood ◽  
Blood Clotting ◽  
Human Origin ◽  
Clotting Time ◽  
Generation Test ◽  
Blood Clotting Time

Autoprothrombin II activity develops when prothrombin preparations of human origin are activated with purified thrombin at pH 8.2. Early during the activation an inhibitor seems to form. Concentrates of the autoprothrombin II can replace serum in the thromboplastin generation test provided platelets are used in the test, but not if a soy bean phosphatide is used. Dogs were given Coumadin in doses that lowered their own autoprothrombin concentration practically to zero. Then while continuing with use of the drug some purified autoprothrombin II was infused intravenously. This was tolerated very well. The autoprothrombin II concentration stayed at normal for 7 hr. In 24 hr none remained. The infusion was also followed by a shortening of the whole blood clotting time.

Heparin Concentrations Correlated To The Activated Whole Blood Clotting Time (Act) During Extracorporeal Circulation

1981 ◽  
Author(s):  
S Stenbjerg ◽  
E Berg ◽  
O K Albrechtsen
Keyword(s):  
Extracorporeal Circulation ◽  
Whole Blood ◽  
Blood Clotting ◽  
Heart Surgery ◽  
Open Heart Surgery ◽  
Open Heart ◽  
Excellent Correlation ◽  
Clotting Time ◽  
Automated Method ◽  
Blood Clotting Time

Heparin levels and ACT were followed during open heart surgery in lo patients. Heparin was assayed by an amidolytic method using substrate S-2222. ACT was determined with an automated method using celite and glass beads as activators of coagulation. Neither the hemodilution nor the depletion of platelets observed during extracorporeal circulation seemed to influence the ACT. An excellent correlation between the ACT and the actual heparin level was found in each patient with coefficients of correlation ranging from 0.73 – 0.97. A slightly better correlation was noticed for values of ACT below 600 seconds. It was concluded that the ACT is a valuable and reliable tool in control of heparinisation during open heart surgery.

Sign in / Sign up

Export Citation Format

Share Document